Bio-Solutions Corp. Expanding in Booming Diabetes Market

News provided by

Aug 29, 2013, 09:05 ET

CORAL SPRINGS, Florida, August 29, 2013 /PRNewswire/ --

On Wednesday, Bio-Solutions Corp. (OTCQB: BISU) announced their Direct Response Infomercial and Marketing Campaign for its flagship product, Type2Defense. Over 30 million people suffer from Type 2 diabetes in the United States, according to seeking alpha. Additionally, it's forecasted that nearly 30 percent of the U.S.'s population will have diabetes by 2050, with most of that percentage facing Type 2.

United Healthcare predicts spending on diabetes will grow significantly over the next 10 years, estimating that the country will spend around $3.4 trillion on the disease. The total cost of diagnosed diabetes in 2012 was $245 billion, as stated by the American Diabetes Association. This was a 41 percent increase from 2007, when costs reached $174 billion.

Bio-Solutions' Type2 Defense is a powder blend of natural ingredients that has been developed to help support healthy blood glucose levels in health-conscious individuals and those diagnosed with Type II Diabetes. With the launch of Type 2 Defense's new infomercial and marketing campaign, BISU takes a significant step in their expansion across the U.S.

The partnership with Direct Response Marketing isn't the first step Bio-Solutions has taken in effort to expand, as they also recently announced they have begun a campaign on Lockerdome.com. Lockerdome.com is the premier destination on the internet for both professional and amateur athletes, with monthly traffic in excess of 14 million visitors. The Company's campaign on the website will allow young athletes with diabetes to interact with pro athletes also suffering from the disease.

For more recent news for BISU, please click on the following links:

http://finance.yahoo.com/news/bio-solutions-corporation-announces-campaign-113000206.html

http://finance.yahoo.com/news/bio-solutions-corporation-launches-type2defense-150000680.html

About Bio-Solutions Corp.

Bio-Solutions Corp. markets new and very effective organic products; our lead product is Type2 Defense™. Type2Defense™ a Diabetic Supplement Drink. Type2Defense™ is a new dietary supplement that has been developed to help support healthy blood glucose levels in health-conscious individuals and those diagnosed with Type 2 Diabetes. The Product's goal is to provide a safe and natural supplement that will assist in the stabilization of healthy glucose levels along with providing strong antioxidants. Consumers can find more information about the company and its products by going to http://www.BioSolutionsCorp.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements which address actual results could differ materially from those expressed or implied in forward-looking statements. These statements are made on the basis of management's views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as management "believes", "expects", "anticipates", "foresees", "forecasts", "estimates" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward looking statements. Management cautions that the ability to attract clients and generate business may be affected by a decline in the Company's financial ratings, the competitive environment, the Company's ability to raise sufficient capital to meet the collateral requirements associated with its current business and to fund the Company's continuing operations and changes in market conditions.

Investor Relations Contact
William Gallagher
+1-210-218-4475
[email protected]

Contact:
FN Media Group, LLC
+1-954-345-0611
[email protected]

SOURCE FN Media Group LLC